CervoMed Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CervoMed Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.01M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $9.74M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $7.14M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 29, 2024 |
| FY2012 | Dec 31, 2012 | $374.5K | Apr 24, 2013 |
| FY2012 | Dec 31, 2011 | $570.5K | Apr 24, 2013 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $71.7K | Apr 23, 2014 |
| FY2013 | Dec 31, 2012 | $374.5K | Apr 23, 2014 |
| FY2011 | Dec 31, 2011 | $570.5K | May 21, 2012 |
| FY2011 | Dec 31, 2010 | $40.2K | May 21, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $71.7K | Apr 23, 2014 |
| FY2012 | Dec 31, 2012 | $138.7K | Apr 24, 2013 |
| FY2011 | Dec 31, 2011 | ($1.74M) | May 21, 2012 |
| FY2011 | Dec 31, 2010 | ($170.2K) | May 21, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($26.97M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($16.29M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($2.17M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($5.80M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($24.10M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($14.19M) | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | ($11.80M) | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | ($18.37M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($1.36M) | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | ($18.04M) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($28.29M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($18.23M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($7.81M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($3.48M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($24.68M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($15.97M) | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | ($11.55M) | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | ($18.96M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($11.35M) | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | ($18.37M) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.82M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $18.80M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $8.44M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $1.34M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $8.50M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $9.43M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $6.62M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $5.75M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $5.09M | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $7.25M | Apr 2, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.45M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($16.53M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($7.45M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($2.57M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($14.50M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($13.55M) | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | ($9.86M) | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | ($10.77M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($12.33M) | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | ($10.77M) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2017 | $447.8K | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $2.3K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $40.3K | Mar 31, 2017 |
| FY2015 | Mar 31, 2015 | $19.2K | May 11, 2015 |
| FY2015 | Dec 31, 2014 | $50.9K | Mar 25, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.88M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $43.08M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $9.97M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $4.16M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $37.84M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $27.73M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $24.11M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $18.20M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $26.15M | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $17.48M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.66M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $3.88M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $2.60M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $13.16M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $2.93M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $2.92M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $3.98M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $2.59M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $4.92M | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $8.30M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.22M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $39.20M | Mar 13, 2026 |
| FY2025 | Dec 31, 2023 | $7.38M | Mar 13, 2026 |
| FY2024 | Dec 31, 2022 | ($33.29M) | Mar 17, 2025 |
| FY2022 | Dec 31, 2021 | $34.91M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $24.81M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $20.13M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $15.61M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $21.23M | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $9.18M | Apr 2, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $0 | Mar 19, 2019 |
| FY2018 | Dec 31, 2017 | $6.93M | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $6.93M | Apr 2, 2018 |
| FY2015 | Dec 31, 2015 | $985.0K | Mar 25, 2016 |
| FY2015 | Sep 30, 2015 | $985.0K | Mar 25, 2016 |
| FY2015 | Mar 31, 2015 | $12.06M | May 11, 2015 |
| FY2015 | Dec 31, 2014 | $12.06M | Mar 25, 2016 |
| FY2014 | Dec 31, 2013 | $7.64M | Apr 3, 2015 |
| FY2013 | Dec 31, 2012 | $1.94M | Apr 23, 2014 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($97.70M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($70.73M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($54.44M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($52.27M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($130.01M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($105.91M) | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | ($91.72M) | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | ($79.92M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($61.55M) | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | ($60.19M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.24M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $9.00M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $7.79M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $4.09M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $37.31M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $18.52M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $14.18M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $7.99M | Mar 17, 2020 |
| FY2019 | Dec 31, 2017 | $8.90M | Mar 17, 2020 |
| FY2018 | Dec 31, 2016 | $1.55M | Mar 19, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | (11) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | (12) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | (1) | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | (8) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | (3) | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | (1) | Apr 2, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 2.04M | Mar 24, 2023 |
| FY2022 | Dec 31, 2021 | 1.95M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | 53.83M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | 6.71M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | 3.24M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | (29) | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | (1) | Apr 2, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9.25M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | 8.70M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | 5.67M | Mar 17, 2025 |
| FY2024 | Aug 16, 2023 | 5.67M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 518,140 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 2.04M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | 64.02M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | 33.48M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | 3.38M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | 967,976 | Mar 19, 2019 |